相关临床试验
9
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1975
进行中（未招募）
5
55.6%
已完成
2
22.2%
招募中
2
22.2%
暂无批准数据
- Oryon Cell Therapies has appointed Kenny Choi, Ph.D., as Chief Technical Officer to lead technical operations and CMC strategy for its autologous neuron replacement medicines. - Dr. Choi brings more than fifteen years of cell therapy manufacturing experience, contributing to over a dozen INDs and three BLAs for autologous cell therapies. - He will oversee transfer of the autologous iPSC-derived dopaminergic neuron manufacturing process from Mass General Brigham to Oryon's own facilities for late-stage development and commercial launch. - Oryon's lead program is in a Phase 1/2a trial for Parkinson's disease, with interim data showing sustained motor improvements in all treated participants.
- Research indicates pembrolizumab, an immunotherapy drug, can reactivate latent HIV in immune cells, making the virus visible to the immune system. - The study involved 32 patients with both cancer and HIV, revealing that pembrolizumab could disrupt HIV's ability to hide within the body. - Experts emphasize the need for further research to determine optimal dosing and safety, especially for individuals without cancer, due to potential toxic side effects. - This study provides a roadmap for exploring new strategies to manipulate the immune system and eliminate the latent HIV reservoir, marking an important step toward finding a cure.
